According to updated recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP), patients and vaccine providers, including pharmacists, should engage in shared clinical decision making when considering pneumococcal conjugate vaccination (PCV13) in persons aged 65 years and older who do not have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant and who have not previously received PCV13.